Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

Journal of Clinical Oncology, Vol 22, No 15 (August 1), 2004: pp. 3070-3079
© 2004 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2004.03.098
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bonneterre, J.
Right arrow Articles by Chapelle-Marcillac, I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bonneterre, J.
Right arrow Articles by Chapelle-Marcillac, I.

Long-Term Cardiac Follow-Up in Relapse-Free Patients After Six Courses of Fluorouracil, Epirubicin, and Cyclophosphamide, With Either 50 or 100 mg of Epirubicin, As Adjuvant Therapy for Node-Positive Breast Cancer: French Adjuvant Study Group

Jacques Bonneterre, Henri Roché, Pierre Kerbrat, Pierre Fumoleau, Marie-Josèphe Goudier, Pierre Fargeot, Philippe Montcuquet, Pierre Clavère, Jean-Claude Barats, Alain Monnier, Corinne Veyret, Jean Datchary, Isabelle Van Praagh, Isabelle Chapelle-Marcillac

From the Centre Oscar Lambret, Lille; Institut Claudius Régaud, Toulouse; Centre Eugène Marquis, Rennes; Centre René Gauducheau, Nantes; Centre Hospitalier de Bretagne Sud, Lorient; Centre Georges-François Leclerc, Dijon; Clinique Saint-Vincent, Besançon; Centre Hospitalier Universitaire Dupuytren, Limoges; Centre Hospitalier Louis Pasteur, Colmar; Centre Hospitalier André Boulloche, Montbéliard; Centre Henri Becquerel, Rouen; Centre Hospitalier, Annecy; and Centre Jean Perrin, Clermont-Ferrand, France

Address reprint requests to Jacques Bonneterre, MD, Département de Sénologie, Centre Oscar Lambret, 3 Rue Frédéric Combemale, 59020 Lille Cedex, France; e-mail: j-bonneterre{at}o-lambret.fr

PURPOSE: To evaluate long-term cardiac function in patients without disease who had received six cycles of fluorouracil 500 mg/m2, epirubicin 50 mg/m2, and cyclophosphamide 500 mg/m2 (FEC 50) or the same regimen with epirubicin 100 mg/m2 (FEC 100) as adjuvant chemotherapy for node-positive breast cancer in the French Adjuvant Study Group–05 trial.

PATIENTS AND METHODS: One hundred fifty patients (FEC 50, n = 65; FEC 100, n = 85) who were without disease and who gave their informed consent were enrolled for long-term cardiac assessment. The assessment included cardiac events occurring after the end of chemotherapy, vital signs, concomitant disease, ECG, isotopic left ventricular ejection fraction (LVEF), and echographic parameters. Abnormal files were blindly reviewed by cardiologists and oncologists.

RESULTS: The median follow-up time was 102 months. After FEC 100, LVEF was less than 50% in five patients (radioisotopic method), and two patients experienced congestive heart failure (CHF) that was possibly related to treatment. Asymptomatic left ventricular dysfunction (LVD) was experienced in 18 patients after FEC 100 and in one patient after FEC 50. In these patients, treatment causality was probable in eight patients. Two additional years after this assessment, all 18 patients were still asymptomatic.

CONCLUSION: After more than 8 years of follow-up, the cardiac toxicity observed after adjuvant treatment with FEC 100 comprised two cases of well-controlled CHF and 18 cases of asymptomatic LVD. In the majority of women with primary breast cancer, the benefits of treatment with FEC 100 in terms of disease-free and overall survival outweigh the risks, and cardiac risk factors should be carefully evaluated in patient selection.

Supported by grants from Pharmacia SA, Saint-Quentin en Yvelines, France.

Presented at the 38th Annual Meeting of the American Society of Clinical Oncology, Orlando, FL, May 18-21, 2002 (abstract 154; poster display/discussion).

Authors' disclosures of potential conflicts of interest are found at the end of this article.




This article has been cited by other articles:


Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
S. Bhatia and L. L. Robison
Cancer Survivorship Research: Opportunities and Future Needs for Expanding the Research Base
Cancer Epidemiol. Biomarkers Prev., July 1, 2008; 17(7): 1551 - 1557.
[Full Text] [PDF]

Home page
 JCOHome page
P. A. Ganz, M. A. Hussey, C. M. Moinpour, J. M. Unger, L. F. Hutchins, S. R. Dakhil, J. K. Giguere, J. W. Goodwin, S. Martino, and K. S. Albain
Late Cardiac Effects of Adjuvant Chemotherapy in Breast Cancer Survivors Treated on Southwest Oncology Group Protocol S8897
J. Clin. Oncol., March 10, 2008; 26(8): 1223 - 1230.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
S.-C. Chen, H.-K. Chang, Y.-C. Lin, S. Hsueh, Y.-C. Cheung, W.-M. Leung, C.-S. Tsai, Y.-F. Lo, H.-P. Tsai, S.-C. Shen, et al.
High Pathologic Complete Response in HER 2-positive Locally Advanced Breast Cancer after Primary Systemic Chemotherapy with Weekly Docetaxel and Epirubicin
Jpn. J. Clin. Oncol., February 12, 2008; (2008) hym172v1.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
B. R.J. H. Bird and S. M. Swain
Cardiac Toxicity in Breast Cancer Survivors: Review of Potential Cardiac Problems
Clin. Cancer Res., January 1, 2008; 14(1): 14 - 24.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
L. W. Jones, M. Haykowsky, E. N. Pituskin, N. G. Jendzjowsky, C. R. Tomczak, R. G. Haennel, and J. R. Mackey
Cardiovascular Reserve and Risk Profile of Postmenopausal Women After Chemoendocrine Therapy for Hormone Receptor Positive Operable Breast Cancer
Oncologist, October 1, 2007; 12(10): 1156 - 1164.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. R. Carver, C. L. Shapiro, A. Ng, L. Jacobs, C. Schwartz, K. S. Virgo, K. L. Hagerty, M. R. Somerfield, D. J. Vaughn, and for the ASCO Cancer Survivorship Expert Panel
American Society of Clinical Oncology Clinical Evidence Review on the Ongoing Care of Adult Cancer Survivors: Cardiac and Pulmonary Late Effects
J. Clin. Oncol., September 1, 2007; 25(25): 3991 - 4008.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. C. Pinder, Z. Duan, J. S. Goodwin, G. N. Hortobagyi, and S. H. Giordano
Congestive Heart Failure in Older Women Treated With Adjuvant Anthracycline Chemotherapy for Breast Cancer
J. Clin. Oncol., September 1, 2007; 25(25): 3808 - 3815.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
H. Roche, P. Fumoleau, M. Spielmann, J.-L. Canon, T. Delozier, D. Serin, M. Symann, P. Kerbrat, P. Soulie, F. Eichler, et al.
Sequential Adjuvant Epirubicin-Based and Docetaxel Chemotherapy for Node-Positive Breast Cancer Patients: The FNCLCC PACS 01 Trial
J. Clin. Oncol., December 20, 2006; 24(36): 5664 - 5671.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Recht
Which Breast Cancer Patients Should Really Worry About Radiation-Induced Heart Disease--And How Much?
J. Clin. Oncol., September 1, 2006; 24(25): 4059 - 4061.
[Full Text] [PDF]

Home page
 Ann OncolHome page
A. Aviles, N. Neri, and M. J. Nambo
Long-term evaluation of cardiac function in children who received anthracyclines during pregnancy
Ann. Onc., February 1, 2006; 17(2): 286 - 288.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
P. Fumoleau, H. Roche, P. Kerbrat, J. Bonneterre, P. Romestaing, P. Fargeot, M. Namer, A. Monnier, P. Montcuquet, M.-J. Goudier, et al.
Long-term cardiac toxicity after adjuvant epirubicin-based chemotherapy in early breast cancer: French Adjuvant Study Group Results
Ann. Onc., January 1, 2006; 17(1): 85 - 92.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
L. Del Mastro and F. Perrone
Reply to "Weekly paclitaxel in elderly breast cancer patients", by C. Smorenburg et al. (Ann Oncol 2005; 16: 1979)
Ann. Onc., December 1, 2005; 16(12): 1979 - 1980.
[Full Text] [PDF]

Home page
 The OncologistHome page
S. Gluck
Adjuvant Chemotherapy for Early Breast Cancer: Optimal Use of Epirubicin
Oncologist, November 1, 2005; 10(10): 780 - 791.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
A. Goldhirsch, J. H. Glick, R. D. Gelber, A. S. Coates, B. Thurlimann, H.-J. Senn, and and Panel Members
Meeting Highlights: International Expert Consensus on the Primary Therapy of Early Breast Cancer 2005
Ann. Onc., October 1, 2005; 16(10): 1569 - 1583.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
J. Bonneterre, C. Bercez, M.-E. Bonneterre, X. Lenne, and B. Dervaux
Cost-effectiveness analysis of breast cancer adjuvant treatment: FEC 50 versus FEC 100 (FASG05 study)
Ann. Onc., June 1, 2005; 16(6): 915 - 922.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. Bonneterre, H. Roche, P. Kerbrat, A. Bremond, P. Fumoleau, M. Namer, M.-J. Goudier, S. Schraub, P. Fargeot, and I. Chapelle-Marcillac
Epirubicin Increases Long-Term Survival in Adjuvant Chemotherapy of Patients With Poor-Prognosis, Node-Positive, Early Breast Cancer: 10-Year Follow-Up Results of the French Adjuvant Study Group 05 Randomized Trial
J. Clin. Oncol., April 20, 2005; 23(12): 2686 - 2693.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. J. Ventura
Cardiotoxicity of Epirubicin Versus Doxorubicin: Cost and Clinical Results
J. Clin. Oncol., April 20, 2005; 23(12): 2873 - 2873.
[Full Text] [PDF]

Home page
 JCOHome page
J. Bonneterre
In Reply:
J. Clin. Oncol., April 20, 2005; 23(12): 2873 - 2874.
[Full Text] [PDF]


About
JCO		 Editorial
Roster		 Advertising
Information		 Librarians &
Institutions		 Rights &
Permissions		 PDA Services

Copyright © 2004 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online